High Net Worth Advisory Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

High Net Worth Advisory Group’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$452K	Hold	1,500	–	–	0.1%	162
2026 Q1	$496K	Hold	1,500	–	–	0.12%	147
2025 Q4	$596K	Hold	1,500	–	–	0.14%	126
2025 Q3	$684K	Hold	1,500	–	–	0.16%	113
2025 Q2	$489K	Hold	1,500	–	–	0.13%	132
2025 Q1	$405K	Hold	1,500	–	–	0.11%	140
2024 Q4	$353K	Hold	1,500	–	–	0.1%	156
2024 Q3	$413K	Hold	1,500	–	–	0.11%	144
2024 Q2	$365K	Hold	1,500	–	–	0.11%	142
2024 Q1	$224K	Hold	1,500	–	–	0.07%	194
2023 Q4	$287K	Hold	1,500	–	–	0.11%	151
2023 Q3	$266K	Hold	1,500	–	–	0.11%	149
2023 Q2	$285K	Hold	1,500	–	–	0.11%	148
2023 Q1	$300K	Hold	1,500	–	–	0.12%	145
2022 Q4	$356K	Hold	1,500	–	–	0.14%	130
2022 Q3	$300K	Hold	1,500	–	–	0.13%	139
2022 Q2	$219K	Buy	1,500 +500	+50%	+$70.9K	0.09%	177
2022 Q1	$163K	Hold	1,000	–	–	0.06%	205
2021 Q4	$170K	Buy	+1,000	New	+$186K	0.06%	201

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

High Net Worth Advisory Group's ALNY Position: Q2 2026 in Review

High Net Worth Advisory Group held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 1,500 shares worth $452K. The position accounts for 0.1% of the portfolio, ranked #162.

High Net Worth Advisory Group first reported a position in ALNY in Q4 2021 and has held it in 19 quarters since. The position peaked at $684K in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

High Net Worth Advisory Group held 1,500 shares of Alnylam Pharmaceuticals worth $452K as of Q2 2026.
High Net Worth Advisory Group left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
Alnylam Pharmaceuticals made up 0.1% of High Net Worth Advisory Group's portfolio in Q2 2026, its #162 holding.
High Net Worth Advisory Group first reported a position in Alnylam Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
High Net Worth Advisory Group's Alnylam Pharmaceuticals position peaked at $684K in Q3 2025.
790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on High Net Worth Advisory Group's 13F filing for Q2 2026, filed 29 Jul 2026.